NasdaqGS - Delayed Quote USD

argenx SE (ARGX)

372.80 +4.20 (+1.14%)
At close: April 26 at 4:00 PM EDT
372.80 0.00 (0.00%)
After hours: April 26 at 5:32 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,226,316.00
1,226,316.00
410,747.00
497,277.00
41,243.00
Cost of Revenue
117,835.00
117,835.00
29,431.00
--
--
Gross Profit
1,108,481.00
1,108,481.00
381,316.00
497,277.00
41,243.00
Operating Expense
1,529,119.00
1,529,119.00
1,105,234.00
857,176.00
521,811.00
Operating Income
-420,638.00
-420,638.00
-723,918.00
-359,899.00
-480,568.00
Net Non Operating Interest Income Expense
92,058.00
92,058.00
22,548.00
2,393.00
4,718.00
Other Income Expense
24,084.00
24,084.00
-27,942.00
-42,239.00
-129,502.00
Pretax Income
-304,496.00
-304,496.00
-729,314.00
-399,743.00
-605,352.00
Tax Provision
-9,443.00
-9,443.00
-19,720.00
8,522.00
3,103.00
Net Income Common Stockholders
-295,053.00
-295,053.00
-709,594.00
-408,265.00
-608,455.00
Diluted NI Available to Com Stockholders
-295,053.00
-295,053.00
-709,594.00
-408,265.00
-608,455.00
Basic EPS
-4.11
-5.16
-13.05
-7.99
-13.40
Diluted EPS
-4.11
-5.16
-13.05
-7.99
-13.40
Basic Average Shares
56,228.72
57,169.25
54,381.37
51,075.83
45,410.44
Diluted Average Shares
56,228.72
57,169.25
54,381.37
51,075.83
45,410.44
Total Operating Income as Reported
-425,049.00
-425,049.00
-720,341.00
-348,746.00
-477,617.00
Total Expenses
1,646,954.00
1,646,954.00
1,134,665.00
857,176.00
521,811.00
Net Income from Continuing & Discontinued Operation
-295,053.00
-295,053.00
-709,594.00
-408,265.00
-608,455.00
Normalized Income
-322,664.32
-322,664.32
-683,066.22
-377,430.53
-513,918.54
Interest Income
92,962.00
92,962.00
24,741.00
3,489.00
5,119.00
Interest Expense
904.00
904.00
2,193.00
1,096.00
401.00
Net Interest Income
92,058.00
92,058.00
22,548.00
2,393.00
4,718.00
EBIT
-303,592.00
-303,592.00
-727,121.00
-398,647.00
-604,951.00
EBITDA
-192,285.00
-192,285.00
-622,779.00
-392,780.00
-601,034.00
Reconciled Cost of Revenue
8,894.00
8,894.00
29,431.00
--
--
Reconciled Depreciation
111,307.00
111,307.00
104,342.00
5,867.00
3,917.00
Net Income from Continuing Operation Net Minority Interest
-295,053.00
-295,053.00
-709,594.00
-408,265.00
-608,455.00
Total Unusual Items Excluding Goodwill
28,495.00
28,495.00
-27,265.00
-42,239.00
-129,502.00
Total Unusual Items
28,495.00
28,495.00
-27,265.00
-42,239.00
-129,502.00
Normalized EBITDA
-220,780.00
-220,780.00
-595,514.00
-350,541.00
-471,532.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
883.68
883.68
-737.22
-11,404.53
-34,965.54
12/31/2020 - 5/18/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IMVT Immunovant, Inc.
27.17
-2.09%
 
BPMC Blueprint Medicines Corporation
93.00
+2.50%
 
MLTX MoonLake Immunotherapeutics
42.49
+0.57%
 
GMAB Genmab A/S
28.15
+2.51%
 
ASND Ascendis Pharma A/S
135.90
-0.75%
 
BGNE BeiGene, Ltd.
153.58
+3.38%
 
KRYS Krystal Biotech, Inc.
156.88
+0.77%
 
CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
BBIO BridgeBio Pharma, Inc.
24.88
+2.26%
 
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%